[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
October 25, 2016

Interventions for Vitiligo

Author Affiliations
  • 1Department of Dermatology, Henri Mondor Hospital and EpiDermE, Université Paris-Est Créteil Val-de-Marne, Créteil, France
  • 2Cochrane Skin Group, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, England
  • 3ISGlobal, Centre for Research in Environmental Epidemiology, Barcelona, Spain

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;316(16):1708-1709. doi:10.1001/jama.2016.12399

Clinical Question  Which interventions are associated with highest efficacy and fewest adverse events for treating vitiligo?

Bottom Line  Combination therapies, particularly those involving some form of light (ie, narrowband UV-B) were associated with more improved repigmentation than monotherapies. There was limited evidence to support the association of UV-A alone and UV-B alone with repigmentation for vitiligo. There was moderate evidence to support the association of UV-A and UV-B, when used in combination with psoralens, topical corticosteroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with improved outcomes for vitiligo. However, combination therapies were associated with more adverse effects.